Literature DB >> 499321

Relationship between plasma concentration and effect of dantrolene sodium in man.

W J Meyler, H W Mols-Thürkow, H Wesseling.   

Abstract

Dantrolen sodium is a muscle relaxant, which is used in the treatment of spasticity. Although it is given chronically, little is known about its pharmacokinetic behaviour. The relationship between the effect of a single oral dose of dantrolene sodium and its plasma concentration in healthy volunteers was studied by measuring the effect on the twitch tension, and in spastic patients on the decrease in muscle hypertonia. On the twitch tension dantrolene gave a depression of 49.1 +/- 9.4% (+/- DS) within 1.15 and 3.45 h after ingestion of 100 mg. The mean maximal plasma concentration was 1.24 +/- 0.32 microgram/ml (+/- SD). The effect and the plasma concentration were correlated. No relationship between the plasma concentration of dantrolene sodium and its effect could be established in patients, although definite activity in 6 out of 7 patients was observed after a single oral dose of 100 mg, and plasma concentration of dantrolene sodium greater than 0.3 microgram/ml were consistenly associated with better results than placebo treatment in 6 out of 7 patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499321     DOI: 10.1007/bf00562062

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

Authors:  B ASHWORTH
Journal:  Practitioner       Date:  1964-04

2.  Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium.

Authors:  G G Harrison
Journal:  Br J Anaesth       Date:  1975-01       Impact factor: 9.166

3.  Dantrolene effects on neuromuscular function in cat soleus muscle.

Authors:  H E Lowndes
Journal:  Eur J Pharmacol       Date:  1975 Jun-Jul       Impact factor: 4.432

4.  Clinical pharmaco--physiology of dantrolene sodium.

Authors:  R Herman; N Mayer; S A Mecomber
Journal:  Am J Phys Med       Date:  1972-12

5.  Effect of dantrolene sodium on calcium movements in single muscle fibres.

Authors:  K Hainaut; J E Desmedt
Journal:  Nature       Date:  1974-12-20       Impact factor: 49.962

6.  Site of action of dantrolene in frog sartorius muscle.

Authors:  J W Putney; C P Biancri
Journal:  J Pharmacol Exp Ther       Date:  1974-04       Impact factor: 4.030

7.  Dantrolene sodium: its effect on extrafusal muscle fibers.

Authors:  A W Monster; Y Tamai; J McHenry
Journal:  Arch Phys Med Rehabil       Date:  1974-08       Impact factor: 3.966

8.  The use of dantrolene sodium in disorders of the central nervous system.

Authors:  S B Chyatte; J H Birdsong
Journal:  South Med J       Date:  1971-07       Impact factor: 0.954

9.  Calcium release from skeletal muscle sarcoplasmic reticulum: site of action of dantrolene sodium.

Authors:  W B Van Winkle
Journal:  Science       Date:  1976-09-17       Impact factor: 47.728

10.  Effect of dantrolene sodium on muscle contraction.

Authors:  O Miglietta
Journal:  Am J Phys Med       Date:  1977-12
View more
  8 in total

Review 1.  Clinical pharmacokinetics in patients with spinal cord injuries.

Authors:  J L Segal; S R Brunnemann
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

2.  The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration.

Authors:  W J Meyler; H Bakker; J J Kok; S Agoston; H Wesseling
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-04       Impact factor: 10.154

Review 3.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

4.  Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat.

Authors:  F G Poelma; R Breäs; J J Tukker
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

Review 5.  Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Authors:  Susanne Muehlschlegel; John R Sims
Journal:  Neurocrit Care       Date:  2008-08-12       Impact factor: 3.532

Review 6.  Clinical review: Treatment of heat stroke: should dantrolene be considered?

Authors:  Eran Hadad; Yoav Cohen-Sivan; Yuval Heled; Yoram Epstein
Journal:  Crit Care       Date:  2004-08-11       Impact factor: 9.097

7.  Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse.

Authors:  Derek W Wang; Ekaterina I Mokhonova; Genevieve C Kendall; Diana Becerra; Yalda B Naeini; Rita M Cantor; Melissa J Spencer; Stanley F Nelson; M Carrie Miceli
Journal:  Mol Ther Nucleic Acids       Date:  2018-02-13       Impact factor: 8.886

8.  Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation.

Authors:  Serena Van; Soumiya Pal; Brittney R Garner; Kate Steed; Vijayalakshmi Sridharan; Shengyu Mu; Nancy J Rusch; Amanda J Stolarz
Journal:  Front Pharmacol       Date:  2021-08-16       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.